Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 697524

[Viral hepatitis].

B Alvermann
View original source ↗Export metadata ↓

Abstract

Viral hepatitis is one of the most frequent infectious diseases of our time. It is of great concern to the epidemiological risk groups such as research laboratories, dialysis units and other public health agencies. The result of epidemiological, immunological, morphological and biochemical studies have demonstrated, that this disease is caused by at least two different viruses. The hepatitis A virus (HAV) induces the type A hepatitis and the hepatitis B virus (HBV) the type B hepatitis. Two antigen-antibody systems are associated with viral hepatitis type B: the hepatitis B-surface antigen (HBsAg) and antibody (anti-HBs) and the hepatitis B-core Antigen (HBcAg) and antibody (anti-HBc). In the last years great progress has been made in the characterization of these distinct viruses. Both can be transmitted to monkeys. Advances in biophysical and biochemical procedures of treatment of hepatitis B sera have already resulted in first vaccination trials.

Explore related subjects

Hepatitis B AntigensHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis VirusesHepatitis, Viral, HumanHumansViral VaccinesEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Alvermann. 1978. [Viral hepatitis].. https://pubmed.ncbi.nlm.nih.gov/697524/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Towards immunotherapy for chronic hepatitis B virus infections.

Chronic liver disease and hepatocellular carcinoma associated with chronic hepatitis B virus (HBV) infection are among the most serious human health problems in highly endemic regions. Although, effective vaccines against HBV have been available for many years, over 350 million people still remain persistently infected with HBV. Current therapies fail to provide long-term control of viral replication in most patients. Viral persistence has been associated with a defect in the development of HBV-specific cell-mediated immunity. Vaccine-based strategies to boost or to broaden the weak virus-specific T cell response of patients with chronic hepatitis B are proposed as a means of terminating this persistent infection.

Hepatitis B Antigens↗
PubMed2002

Immunogenicity of hepatitis B vaccines: implications of immune memory.

The subunit recombinant hepatitis B virus (HBV) vaccines available in the US differ in hepatitis B surface antigen content. Clinical studies have linked higher antigen formulations with enhanced peak protective antibody levels. This is important for the elderly, smokers, the obese, and the immunocompromised. Immune memory, which is responsible for prolonged protection when HBV vaccine-induced antibody levels become undetectable, may be related to antigen persistence on immunologically active cells. Antigen persistence may be related to antigen content of the vaccine and thereby influences the duration of immunity. Proof of this concept will require additional studies of immune memory in HBV.

Hepatitis B Antigens↗